Free Trial
→ My prediction for December 8th (From Behind the Markets) (Ad)tc pixel
NASDAQ:SXTP

60 Degrees Pharmaceuticals Q3 2026 Earnings Date & Estimates

60 Degrees Pharmaceuticals logo
$0.55 -0.05 (-8.19%)
Closing price 11/9/2026 04:00 PM Eastern
Extended Trading
$0.57 +0.03 (+5.09%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

60 Degrees Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from 60 Degrees Pharmaceuticals in Q3 2026

60 Degrees Pharmaceuticals is expected to post earnings of -$0.61 per share on revenue of $270 thousand. In the same quarter a year earlier 60 Degrees Pharmaceuticals reported -$2.64 per share on revenue of -$9.13 thousand. 60 Degrees Pharmaceuticals last reported on August 14, 2026, posting -$0.90 per share and missing the -$0.74 consensus estimate. 60 Degrees Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.61
Expected Revenue
$270 thousand
Prior-Year EPS
-$2.64
Prior-Year Revenue
-$9.13 thousand

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.90 (Missed by -$0.16)
Last Quarter Revenue
$207.90 thousand
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

60 Degrees Pharmaceuticals Q3 2026 Earnings FAQ

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

60 Degrees Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect 60 Degrees Pharmaceuticals to post earnings of -$0.61 per share for Q3 2026.

The consensus revenue estimate for 60 Degrees Pharmaceuticals is $270 thousand for Q3 2026.

60 Degrees Pharmaceuticals Earnings Headlines

60 Degrees Pharmaceuticals (SXTP) Set to Post Quarterly Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179421
60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3703667/60-degrees-reports-negative-babesia-pcr-results-in-completed-expanded-access-patients-stock-down.aspx
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
 |  Behind the Markets (Ad)
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390168/0/en/60-degrees-pharmaceuticals-announces-partnership-with-the-university-of-southern-mississippi-to-evaluate-castanospermine-in-nonclinical-models-of-alpha-gal-syndrome.html
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
October 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3388968/0/en/60-degrees-pharmaceuticals-announces-clinical-improvement-and-negative-pcr-results-in-all-completed-expanded-access-babesiosis-study-patients.html
60 Degrees To Unblind Babesiosis Study In January 2027; Plans FDA Meeting Following Interim Review
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3696903/60-degrees-to-unblind-babesiosis-study-in-january-2027-plans-fda-meeting-following-interim-review.aspx
See More 60 Degrees Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals (NASDAQ:SXTP), Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent.

Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults. Tafenoquine is designed to provide malaria prophylaxis through a longer-acting dosing regimen than many conventional preventive treatments. The company has also evaluated tafenoquine and related opportunities in additional infectious-disease applications.

Founded in 2010, 60 Degrees Pharmaceuticals is based in Washington, D.C., and serves the U.S. market through its focus on regulatory development and commercialization of anti-infective products. The company was founded by Geoffrey Dow, who has served as its chief executive officer. Its broader strategy involves advancing therapies for diseases with significant unmet medical needs and pursuing opportunities to expand access to its products through commercial and strategic partnerships.

View 60 Degrees Pharmaceuticals Profile
Earnings Tools